Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prostaglandin E1 (PGE1), also known as alprostadil, is a naturally occurring prostaglandin that acts as a potent vasodilator and smooth muscle relaxant. It is used to maintain the patency of the ductus arteriosus in neonates with congenital heart defects and to treat erectile dysfunction.
PGE1 exerts its effects primarily through binding to specific G protein-coupled receptors known as EP receptors—subtypes EP1, EP2, EP3, and EP4. This binding leads to vasodilation, inhibition of platelet aggregation, and relaxation of smooth muscle tissue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prostaglandin E1 (PGE1).